Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial

Susai, Subash Raj, Föcking, Melanie, Mongan, David, Heurich, Meike ORCID: https://orcid.org/0000-0003-0105-2702, Coutts, Fiona, Egerton, Alice, Whetton, Tony, Winter-van Rossum, Inge, Unwin, Richard D., Pollak, Thomas A., Weiser, Mark, Leboyer, Marion, Rujescu, Dan, Byrne, Jonah F., Gifford, George W., Dazzan, Paola, Koutsouleris, Nikolaos, Kahn, René S., Cotter, David R. and McGuire, Philip 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49 (4) , pp. 893-902. 10.1093/schbul/sbac201

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (404kB) | Preview

Abstract

Background and Hypothesis Treatment response to specific antipsychotic medications is difficult to predict on clinical grounds alone. The current study hypothesizes that the baseline complement pathway activity predicts the treatment response and investigates the relationship between baseline plasma biomarkers with treatment response to antipsychotic medications. Study Design Baseline plasma samples were collected from first episode of psychosis patients (n = 243) from a multi-center clinical trial. The participants were treated with amisulpride for 4 weeks. Levels of complement and coagulation proteins at baseline were measured using both data-dependent and data-independent mass spectrometry approaches. The primary outcome was remission status at 4 weeks and the secondary outcomes included change in psychotic and functional symptoms over the period of treatment. In addition, immunoassays were performed at baseline for complement C1R, as well as for activation markers C4a and sC5b-9. Study Results The plasma level of complement variant C4A was significantly associated with remission at 4 weeks. Moreover, higher levels of several complement and coagulation pathway proteins were associated with a reduction in psychotic symptoms and an improvement in functioning. Immunoassays showed an association of baseline levels of C1R and C4a as well as complement activation marker sC5b-9 levels with treatment response. Conclusion The results demonstrated that the response to antipsychotic treatment might be related to pre-treatment levels of plasma complement and coagulation pathway proteins. This is consistent with independent evidence associating immune dysfunction with the pathophysiology of psychosis. Moreover, these results inform the development of novel therapeutic approaches that target the complement system for psychosis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Oxford University Press
ISSN:	0586-7614
Date of First Compliant Deposit:	20 March 2023
Date of Acceptance:	14 March 2023
Last Modified:	17 Aug 2023 16:30
URI:	https://orca.cardiff.ac.uk/id/eprint/157807

Actions (repository staff only)

Edit Item